Thank you to the National Cancer Institute (NCI) for highlighting Repare Therapeutics' investigation of camonsertib, guided by the Oncology Center of Excellence's Project Optimus to optimize dose and schedule. We are grateful to our study team - nurses, study coordinators and investigators - for their close monitoring and dedication in the development of camonsertib. Learn more here:
https://lnkd.in/eBgYzP3b#precisiononcology#clinicaltrials
So satisfying to work with a team and investigators ready to make simple and impactful decisions that create novel way to help patients, greatful for the recognition!
This inspiring story about the promising advancements in cancer treatment with theranostics highlights how innovative therapies can improve quality of life for those with advanced cancer. This is a must-read for anyone interested in the future of oncology and medical innovation. Check out the full story! #CancerTreatment#MedicalInnovation#Oncology#Theranostics
Steve Reed, a 77-year-old living with metastatic prostate cancer since 1998, faced significant challenges with chemotherapy. After 18 cycles, the side effects became unbearable. In January 2023, his oncologist suggested a new theranostic drug, Pluvicto (177Lu-PSMA-617). This treatment targets cancer cells with minimal side effects, offering Reed a better quality of life. Since starting Pluvicto, he experienced virtually no side effects and resumed activities he loves, including travel. Theranostics is revolutionizing cancer treatment, providing new hope for patients with advanced stages of the disease. #CancerTreatment#Theranostics#Pluvicto#MedicalInnovation#Oncologyhttps://lnkd.in/efiKbxgJ
EVP & Expert Advisor, Oncology, Head Center of Excellence, Lumanity, Scientific/Clinical/Strategic Advisory Boards at ImmunOS, Pearl Bio, Skipper BioMed
Thanks for alerting me to this timely article, Paul Hurst. Be sure to join us at Emerging Frontiers in Oncology on March 21 in Boston where we will talk about precision oncology, the pros and the cons.
https://lnkd.in/eXUFGqFG
“Classifying cancers according to their molecular characteristics would expedite the access of millions of people to effective treatments; it is also the first step towards precision oncology and a deeper biological understanding of how cancer works.”
Nature 626, 26-29 (2024)
I want to share this great article in Nature by the team at the leading French oncology research center, Gustave Roussy, about why and how we urgently need to reframe the way we see, treat and pay for cancer care, because cancer is a cell problem, not an organ problem. We continue to live in outdated paradigms that prevent us from being more effective in treating and caring for patients. We may all suffer from cancer at some point... Build knowledge. https://lnkd.in/dmizGQWq
The quest for a novel target for pancreatic cancer has become an urgent imperative due to the exceptionally challenging nature of this disease. Pancreatic cancer is notorious for its aggressive behavior, late-stage diagnosis, and limited treatment options. Its five-year survival rate remains alarmingly low, and the existing therapies often offer only modest benefits. Thus, identifying a fresh and more precise therapeutic target is crucial to revolutionize the treatment landscape. Such a breakthrough could potentially lead to more effective, less toxic treatments, earlier detection methods, and improved patient outcomes. Pancreatic cancer, in its current state, demands innovative approaches, and the pursuit of a novel target is a pressing necessity in the relentless battle against this deadly malignancy. Read our latest blog in this topic and do share your opinions.
Steve Reed, a 77-year-old living with metastatic prostate cancer since 1998, faced significant challenges with chemotherapy. After 18 cycles, the side effects became unbearable. In January 2023, his oncologist suggested a new theranostic drug, Pluvicto (177Lu-PSMA-617). This treatment targets cancer cells with minimal side effects, offering Reed a better quality of life. Since starting Pluvicto, he experienced virtually no side effects and resumed activities he loves, including travel. Theranostics is revolutionizing cancer treatment, providing new hope for patients with advanced stages of the disease. #CancerTreatment#Theranostics#Pluvicto#MedicalInnovation#Oncologyhttps://lnkd.in/efiKbxgJ
🚨 Exciting news alert! 🚨 The groundbreaking trial of a new bowel cancer drug has shown incredible results, shrinking 60% of tumors. This is a huge leap forward in the fight against cancer. Check out the full article in The Sun to learn more about this game-changing development. #CancerResearch#MedicalInnovation#HealthBreakthroughshttps://ift.tt/5C0VaqE
Executive Business Services & Advisory Consultant | Based in Washington, DC | IT and Finance Program Management Specialist | 20 Years Exp. | Accenture, IBM, and KPMG, LLP Alum
In CURE Today: For patients with muscle-invasive bladder cancer, it’s crucial to speak with a multidisciplinary team to figure out the best treatment approach, an expert told CURE®, noting that there are both pros and cons to bladder removal and bladder-preserving options. Click here to read the article: https://lnkd.in/gP3QCpjB
In this month of Breast Cancer Awareness, our Candriam experts share their views on advances in healthcare and oncology in their latest paper.
#candriam#investing4tomorrow
A/Prof Jim Coward, Medical Oncologist and Chair of Icon Group's Medical Oncology Research Committee, recently shared his insights on the future of cancer treatments. His interview highlights promising developments in Phase I trials and the growing potential of Antibody-Drug Conjugates (ADCs) to offer new hope for cancer patients.
Read the full interview to learn more about these advancements in cancer care: https://lnkd.in/ectQdjkB#cancercare#cancerresearch#oncology#healthcare
Chief Medical Officer at Repare Therapeutics
2moSo satisfying to work with a team and investigators ready to make simple and impactful decisions that create novel way to help patients, greatful for the recognition!